Agilent launches reversed-phase column for biotherapeutic development

Agilent Technologies has announced the launch of its AdvanceBio RP-mAb, a reversed-phase columns for use in biotherapeutic developments.

They are optimised to separate monoclonal antibodies, also known as mAbs, which are the primary proteins researchers study to develop biotherapeutics, biosimilars and biobetters.

The columns leverage Agilent's Poroshell technology for fast, high-resolution analysis of intact mAbs. They measure 3.5 micrometres, are superficially porous to 450 angstroms and are stable to 600 bar.

Designed and manufactured solely by Agilent for premium, end-to-end quality control, the new product is part of the company's wide range of offerings aimed at supporting biological research and drug development by increasing the accuracy and productivity of biocolumns technology.

Anne Jones, Agilent's vice president of chemistries, said: "Its 450 angstrom pore size is optimal for obtaining higher resolution – a vital factor for researchers, as mAbs are notoriously difficult to analyse."

This comes after the firm launched its Cary 610 and 620 Fourier transform infrared spectrometer microscopes earlier this month.